Paper41300964
Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions.
Sarti S and 13 others. Cancers (Basel), 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions. Papers, record 41300964. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41300964
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| GOIRC2025 | Italian Oncology Group of Clinical Research | PubMed |
Source PubMed
References88
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25858804 | Immune checkpoint blockade: a common denominator approach to cancer therapy. | Cancer Cell | 2015 | https://conductscience.org/library/papers/25858804 | PubMed |
| 2 | 22580612 | MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. | Oncogene | 2013 | https://conductscience.org/library/papers/22580612 | PubMed |
| 3 | 16034008 | Benign breast disease and the risk of breast cancer. | N Engl J Med | 2005 | https://conductscience.org/library/papers/16034008 | PubMed |
| 4 | 39513557 | Most young female cancer survivors are at minimal risk for obstetric problems. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/39513557 | PubMed |
| 5 | 20512124 | An autoimmune-mediated strategy for prophylactic breast cancer vaccination. | Nat Med | 2010 | https://conductscience.org/library/papers/20512124 | PubMed |
| 6 | 35584336 | Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. | J Clin Oncol | 2022 | https://conductscience.org/library/papers/35584336 | PubMed |
| 7 | 28661758 | Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I). | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28661758 | PubMed |
| 8 | 31022829 | A Comparison of Plasmid DNA and mRNA as Vaccine Technologies. | Vaccines (Basel) | 2019 | https://conductscience.org/library/papers/31022829 | PubMed |
| 9 | 29404275 | Oncogenic Viruses and Breast Cancer: Mouse Mammary Tumor Virus (MMTV), Bovine Leukemia Virus (BLV), Human Papilloma Virus (HPV), and Epstein-Barr Virus (EBV). | Front Oncol | 2018 | https://conductscience.org/library/papers/29404275 | PubMed |
| 10 | 22747619 | The development and validation of the hypertension evaluation of lifestyle and management knowledge scale. | J Clin Hypertens (Greenwich) | 2012 | https://conductscience.org/library/papers/22747619 | PubMed |
| 11 | 37490322 | Mapping Factors That Affect the Uptake of Digital Therapeutics Within Health Systems: Scoping Review. | J Med Internet Res | 2023 | https://conductscience.org/library/papers/37490322 | PubMed |
| 12 | 31474332 | Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. | Lancet | 2019 | https://conductscience.org/library/papers/31474332 | PubMed |
| 13 | 16754727 | Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. | JAMA | 2006 | https://conductscience.org/library/papers/16754727 | PubMed |
| 14 | 38704119 | Making Informed Choices On Incorporating Chemoprevention into carE (MiCHOICE, SWOG 1904): Design and methods of a cluster randomized controlled trial. | Contemp Clin Trials | 2024 | https://conductscience.org/library/papers/38704119 | PubMed |
| 15 | 27737975 | Identification and management of women with a family history of breast cancer: Practical guide for clinicians. | Can Fam Physician | 2016 | https://conductscience.org/library/papers/27737975 | PubMed |
| 16 | 36131288 | Digital health applications and the fast-track pathway to public health coverage in Germany: challenges and opportunities based on first results. | BMC Health Serv Res | 2022 | https://conductscience.org/library/papers/36131288 | PubMed |
| 17 | 28465452 | Human Tumor Antigens Yesterday, Today, and Tomorrow. | Cancer Immunol Res | 2017 | https://conductscience.org/library/papers/28465452 | PubMed |
| 18 | 37149701 | Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women. | Br J Cancer | 2023 | https://conductscience.org/library/papers/37149701 | PubMed |
| 19 | 31278729 | Review: Patient-controlled transdermal 4-hydroxytamoxifen (4-OHT) vs. oral tamoxifen: A systematic review and meta analysis. | Pak J Pharm Sci | 2019 | https://conductscience.org/library/papers/31278729 | PubMed |
| 20 | 2593165 | Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. | J Natl Cancer Inst | 1989 | https://conductscience.org/library/papers/2593165 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42774746 | Engineering probiotic consortia to improve chemotherapy tolerance and reduce toxicity in breast cancer patients: a new frontier in supportive precision oncology. | Oncol Rev | 2026 | https://conductscience.org/library/papers/42774746 | PubMed |
| 41943164 | Effect of VSOR/VRAC blocker tamoxifen on contractile activity of primary neonatal cardiomyocytes and isolated perfused heart. | BMC Res Notes | 2026 | https://conductscience.org/library/papers/41943164 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 | NCBI Gene |
| NR4A1 | 3164 | PubTator's text mining | https://conductscience.org/library/genes/3164 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41300964
GET https://conductscience.org/api/papers/v1/41300964/references?page=2